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Abstract: Histone deacetylase (HDAC) and histone acetyltransferase (HAT) regulate transcription
and the most important functions of cells by acetylating/deacetylating histones and non-histone
proteins. These proteins are involved in cell survival and death, replication, DNA repair, the cell
cycle, and cell responses to stress and aging. HDAC/HAT balance in cells affects gene expression
and cell signaling. There are very few studies on the effects of stroke on non-histone protein
acetylation/deacetylation in brain cells. HDAC inhibitors have been shown to be effective in
protecting the brain from ischemic damage. However, the role of different HDAC isoforms in
the survival and death of brain cells after stroke is still controversial. HAT/HDAC activity depends
on the acetylation site and the acetylation/deacetylation of the main proteins (c-Myc, E2F1, p53,
ERK1/2, Akt) considered in this review, that are involved in the regulation of cell fate decisions.
Our review aims to analyze the possible role of the acetylation/deacetylation of transcription factors
and signaling proteins involved in the regulation of survival and death in cerebral ischemia.
Keywords: cerebral ischemia; histone acetylation; histone deacetylases; histone deacetylase in-
hibitors; non-histone proteins
1. Introduction
Acetylation of histones and non-histone proteins modulates gene expression and
signaling in cells. Changes in the secondary structure of proteins by acetylation leads to a
change in their enzymatic activity, subcellular localization and protein-protein
interactions [1].
The study of non-histone protein acetylation/deacetylation began after the success
of the clinical use of histone deacetylase inhibitors (HDACs) in the treatment of various
forms of cancer and was driven by the search for the causes of cytotoxicity of nonselective
HDAC inhibitors (HDACi) [2]. Non-histone substrates of HDAC and acetyltransferases
(HAT) have been identified, which are tumor suppressors, signaling mediators, steroid
receptors and transcription factors [3,4]. The number of identified proteins in which activity
is regulated by acetylation/deacetylation to date is certainly lower than the actual amount
represented by acetylome in vivo.
There are very few studies on the non-histone protein acetylation/deacetylation in
brain cells, and there is apparently no data on these processes in stroke. Our review aims to
analyze the possible role of acetylation/deacetylation of transcription factors and signaling
proteins involved in the regulation of apoptosis in ischemia.
2. Protein Acetylation and Deacetylation Enzymes
Acetylation and deacetylation of histones and non-histone proteins is carried out by
histone deacetylase (HDAC) and histone acetyltransferase (HAT). Histone acetyltrans-
ferases (HATs) transfer acetyl groups from acetyl coenzyme A (Acetyl Co-A) to the ε-amino
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group of lysine residues, while histone deacetylases (HDACs), on the contrary, catalyze the
removal of acetyl groups. Since histones were the first identified targets of deacetylases and
acetyltransferases, these enzymes were named histone deacetylases and histone acetyltrans-
ferases. However, in addition to regulating transcription, HAT/HDAC regulate the most
important functions of cells by acetylating/deacetylating a huge number of non-histone
proteins, which have always been their evolutionarily primary targets [3]. These proteins
regulate cell survival and death, replication, DNA repair, the cell cycle, and cell responses
to stress and aging.
3. Histone Acetyltransferases
Depending on the intracellular localization, HATs are classified into types A or B,
which either contain or do not contain a bromodomain [5] (Figure 1). Type A HATs are
mainly responsible for acetylation associated with transcription. Type B cytoplasmic HATs
acetylate de novo synthesized histones and non-histone proteins. Based on sequence ho-
mology as well as common structural features and functions, HATs have been grouped into
three main categories: GNAT (GCN5-related N-Acetyltransferases), EP300/CREBBP (E1A
binding protein p300/CREB-binding protein), and the MYST family. PCAF (P300/CBP-
associated factor), belonging to the GNAT family, is the most important enzyme that
acetylates non-histone proteins [6]. In addition, PCAF is the only HAT in which, even with
a complete knockout, no phenotypic changes are observed [7]. In the model of photothrom-
botic stroke (PTS), it was shown that PCAF is poorly expressed in normal neurons and
astrocytes of the rat cerebral cortex. However, the protein level increased in neurons and
especially in the astrocytes of the penumbra 4–24 h after PTS [8]. Intracellular localiza-
tion and activity of PCAF is regulated by its acetylation. Autoacetylation of PCAF, or its
acetylation by p300, enhances the acetyltransferase activity of the enzyme and leads to its
translocation into the nucleus. Deacetylation of PCAF by HDAC3 decreases the activity of
the enzyme and promotes its cytoplasmic localization [9].
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matin conformation in the cell according to the HAT/HDAC balance. The different families and Figure 1. Histone acetyltransferase (HAT) and histone deacetylase (HDAC) classification.
The chromatin conformation in the cell according to the HAT/HDAC balance. The different families
and classes of enzymes are noted. Type A HATs responsible for acetylation associated with transcrip-
tion. Type B cytoplasmic HATs acetylate de novo synthesized histones and non-histone proteins. Ac
= Acetyl; CBP = cyclic adenosine monophosphate response element-binding (CREB) protein; GNAT
= Gcn5-related N-acetyltransferases; PCAF = p300/CBP-associated factor; GCN5 = general control of
amino acid synthesis protein 5-like 2; ELP3 = elongation protein 3; MYST = MOZ/YBF2/SAS2/TIP60;
TIP60 = TAT interacting proteins 60; SIRT 1–7 = sirtuins.
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HAT1 is considered as a cytoplasmic protein. The enzyme acetylates newly synthe-
sized histones in the cytoplasm before being imported into the nucleus [10]. PTS-induced
upregulation of HAT1 and PCAF occurred in the penumbra due to HAT1 and PCAF over-
expression in the cytoplasm of neurons and astrocytes [8]. This indicates the possibility of
acetylation of the cytoplasmic proteins HAT1 and PCAF during cerebral ischemia.
4. Histone Deacetylases
Four classes of HDACs are distinguished according to the functions, cell localization,
and expression patterns in mammals. Classes I (HDACs-1, -2, -3 and -8), II (HDACs-
4, -5, -6, -7, -9 and -10) and IV (HDAC-11) are zinc-dependent enzymes, while in class
III enzymes (Sirtuins), nicotinamide adenine dinucleotide (NAD+) acts as a cofactor and
HDAC1 and HDAC2 are parts of Sin3, NuRD, CoREST, and NODE complexes that suppress
transcription [11] (Figure 2). HDAC1 may play a dual role in the regulation of neuronal
life and death. If HDAC1 interacts with HDAC3, it leads to neuronal death, but it is
neuroprotective when it interacts with HDRP, a shorter form of HDAC9 [12]. HDAC3
is part of the NCoR/SMRT corepressor complex and regulates gene expression by the
deacetylation of histones, as well as a number of non-histone proteins [13]. Once cerebral
ischemia has occurred, HDAC1 is able to enter the cell cytoplasm [14]. In contrast to
HDAC1 and HDAC3, HDAC2 expression is increased not only in the nuclei of neurons, but
also in the nuclei of penumbral astrocytes on the first day after PTS and during the recovery
period [15]. It has been shown that an increase in HDAC2 expression plays a crucial role
in the survival or death of neurons in the peri-infarction region of the cerebral cortex of
animals, both in the PTS model and after middle cerebral artery occlusion (MCAO) [16,17].
Inhibition of HDAC2 promoted the restoration of brain function, while overexpression
increased stroke-induced functional impairment. At the same time, inhibition of other
HDAC isoforms was ineffective ([17,18]. A recent study by Shoyaib et al. has shown
no substantial effect of Panobinostat (pan-HDACs inhibitors) or Entinostat (inhibitors
of HDAC1/HDAC3) on motor recovery in mice after photothrombotic stroke. This was
accompanied by negligible changes of parvalbumin-positive neurons and comparable
infarct volumes among experimental groups, while a dose-dependent increase in acetylated
histone 3 was observed in the peri-infarct cortex of drug-treated animals [19].
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dependent enzymes.
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Another class I histone deacetylase HDAC8 is present mainly in the cytoplasm of
neurons and astrocytes of the cerebral cortex, amygdala, hippocampus, and hypothala-
mus [15,20]. HDAC8 expression in neurons and astrocytes of the cerebral cortex of mice
was significantly increased during the recovery period, from 3 to 14 days after PTS [15].
Overexpression of HDAC3, HDAC6, and HDAC11 was observed in the penumbra at
3 and 24 h after MCAO and persisted for a week after reperfusion. Inhibition of HDAC3 or
HDAC6 expression increased cell viability [21]. After PTS, HDAC6 expression was high
both on the first day, and in the early recovery period [22]. Decreased HDAC6 activity
caused by the selective HDAC6 inhibitors tubastatin A [23] or HPOB [22], restores acety-
lation of α-tubulin, a classic substrate of HDAC6, and reduces apoptosis of nerve cells,
thereby protecting the brain tissue from damage. HDAC6 is a predominantly cytoplas-
mic enzyme. However, HDAC6 localization in cells is regulated by nuclear import and
export [24]. HDAC6 could have nuclear localization and interoperate with HDAC11 [25],
p300 [26], repressor complex LCoR and p65 subunit of nuclear factor-κB [27].
It is known that class II HDACs recruit class I HDACs to form the NCoR/SMRT com-
plex, thereby suppressing the transcription of a number of proteins [28]. Data on the role of
HDAC4 in neurodegeneration and neuroprotection are contradictory.
Some authors reported the ability of HDAC4 to support neuronal survival [29,30].
Others did not find a relationship between neuronal survival and HDAC4 expression [22,
31]. HDAC4 rapidly translocates into the nucleus in response to a decrease in potassium or
an increase in glutamate in cultured neurons, which induces neuronal cell death [32,33].
Kassis et al. reported that HDAC4 nuclear localization promotes brain recovery after
stroke [34]. A decrease in HDAC4 expression and its translocation into neuronal nuclei
was noted both on the first day, and 2 weeks after stroke [22,35]. It has been shown that
miR-29a-3p strengthened the effect of dexmedetomidine on improving neurologic damage
in newborn rats with hypoxic-ischemic brain damage by inhibiting HDAC4 [36].
Another representative of the HDAC IIa class, HDAC5, is involved in the differentia-
tion of neurons, and regulates the survival of neurons in the cerebral cortex through the
action of factors that cause apoptosis [37]. Overexpression of HDAC5 and its nuclear local-
ization caused apoptosis of cultured neurons of the granular layer of the cerebellum [38].
On the other hand, the nuclear export of HDAC5 stimulates the regeneration of sensory
neuron axons after injury [39]. HDAC4 and HDAC5 physically interact with the tran-
scription factor downstream regulatory element antagonist modulator (DREAM). A recent
study showed that the DREAM/HDAC4/HDAC5 complex epigenetically down-regulates
ncx3 gene transcription after stroke, and the pharmacological inhibition of class IIa HDACs
reduces stroke-induced neurodetrimental effects [40].
Sirtuins are class III histone deacetylases. Seven sirtuins, 1–7 have been identified
in mammals. Sirt1 and Sirt6 are mainly localized in the cell nucleus, Sirt7 in the nucleoli,
Sirt3, Sirt4 and Sirt5 are mitochondrial proteins, and Sirt2 is located in the cytoplasm.
Sirt1 and Sirt2 are the most studied. There is a significant amount of data indicating the
neuroprotective properties of Sirt1 in ischemic stroke, brain injury, and neurodegenerative
diseases [41–43]. Sirt1 knockout mice displayed larger infarct volumes after ischemia than
their wild-type counterparts in the MCAO model [44], while mice with Sirt1 overexpression
were more resistant to ischemia [45]. Sirt1 activators reduce the size of the infarction [46].
In contrast, Sirt2 is usually assigned a proapoptotic role, and pharmacological inhibi-
tion or knockdown of Sirt2 can prevent neuronal apoptosis in ischemic stroke [41,47,48].
Our results show that during the recovery period after PTS, an increase in Sirt1 and
Sirt2 is observed, but with opposite functional consequences. Nevertheless, several stud-
ies indicate that the function of Sirt2 in the ischemic brain is much more complex than
simply pathological or neuroprotective and depends on the cellular and intracellular lo-
calization of different enzyme isoforms, the level of its phosphorylation, and the type of
substrate [41,42,48]. It has been shown that acute cerebral ischemia-induced downregula-
tion of Sirt3 protein expression contributes to neuronal injury via damaging mitochondrial
function [49]. Sirt3 plays a protective role in ischemic stroke via regulating HIF-1α/VEGF
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signaling in astrocytes [50]. Moreover, SIRT6 exerts a protective role in ischemic stroke by
blunting I/R-mediated damage to the blood-brain barrier [51].
5. Post-Translational Modifications of HDACs
Post-translational modifications of HDACs are capable of affecting their deacetylase
activity. Thus, phosphorylation of HDAC2 at serine S394, S422, and S424 activates the
enzyme [52], while S-nitrosylation of cysteine (C262 and C274), on the contrary, inhibits
the enzyme in muscular dystrophy in mice [53]. In a model of cardiac hypertrophy in
mice, it was shown that in the nuclei of cardiomyocytes, PCAF interacts with HDAC2 and
acetylates the protein at lysine 75. This leads to the phosphorylation of the protein (S394)
and its activation, and HDAC5 moves from the cytoplasm of cells to the nucleus, where it
deacetylates HDAC2, reducing the hypertrophy of cardiomyocytes [54]. This illustrates the
two opposing actions of prohypertrophic HDAC class I and antihypertrophic HDAC class
IIa, which should be considered when developing new HDAC inhibitors, since HDAC IIa
inhibitors can aggravate the disease by acetylating and thereby activating other HDACs.
6. Biological Activity of HDAC Inhibitors
HDAC inhibitors (iHDACs), which were effective in protecting the brain from is-
chemic damage, belonged to two chemical groups: (a) small carboxylates: valproic acid
(VPA), sodium butyrate (SB), and sodium 4-phenylbutyrate (4-PBA); (b) Hydroxamate-
containing compounds: suberoylanilide hydroxamic acid (SAHA) and trichostatin A
(TSA) and others [55]. In cellular and animal models of ischemia, iHDACs have been
shown to protect the brain from excitotoxicity, oxidative stress, endoplasmic reticulum
stress, apoptosis, inflammation, and BBB damage [40,56,57]. They also promote angio-
genesis, neurogenesis, and stem cell migration to damaged areas, which leads to func-
tional recovery after brain ischemia [58,59]. However, classic iHDACs are not selective.
They inhibit HDACs in classes I or II, or both. The use of nonselective iHDACs for cancer
treatment in humans has caused side effects ranging from minor (e.g., diarrhea, anorexia, de-
hydration) to severe (e.g., myelosuppression, thrombocytopenia,
and cardiotoxicity) [60–62]. Because iHDACs were originally developed to treat a variety
of cancers, they can treat chronic neurodegeneration and promote recovery from stroke
without the fear of increasing the probability of cancer developing. However, the use of
nonselective iHDACs for the treatment of neurodegenerative diseases or the repercussions
of stroke can have a number of side effects. VPA and TSA, nonselective iHDACs, promote
cell cycle arrest by preventing the formation of mature oligodendrocytes [63,64] and have a
cytotoxic effect on cultured cerebellar and cortical neuronal cells [65–67]. In addition, the in-
crease of double-stranded DNA breaks and apoptosis were shown in cortical neurons when
only nonselective iHDAC was administered [67] or in combination with DNA damaging
agents [68]. Nonselective iHDACs cause the death of dopaminergic neurons and neurons
in the ventral midbrain [69,70]. SAHA negatively affects the survival of oligodendrocyte
progenitor cells and prevents their differentiation into mature oligodendrocytes, which
can slow down axonal myelination during brain repair after injury, as well as in the treat-
ment of mental and neurodegenerative conditions [71]. The HDAC3 inhibitor RGFP966
ameliorated ischemic brain damage by downregulating the AIM2 inflammasome [72].
Brain penetrant benzazepine-based HDAC6 inhibitors reduced cerebral infarction and
alleviated neurobehavioral deficits in post-ischemic treatment in rats with transient middle
cerebral artery occlusion (MCAO) [73].
Although HATs, like HDACs, are involved in tumor progression and their inhibitors
may be useful in the treatment of cancer, they are not currently used in clinical practice.
Due to their ability to be a part of protein complexes, modern HAT inhibitors are unstable,
have low activity, or lack of selectivity [74]; however, the development of more selective
HAT inhibitors will undoubtedly be of interest for future cancer therapy [75], and possibly
for stroke therapy.
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The active search for non-histone HAT/HDAC targets is due to the search for the
causes of the cytotoxicity of nonselective iHDACs used in the treatment of various forms
of cancer. Changes in the acetylation pattern of the transcription factors or signaling
proteins that regulate cell survival or death by nonselective iHDACs can reactivate or
inhibit them, leading to a change in cell fate. Besides, the use of nonselective iHDACs
may cause dysfunction of chaperones and the inhibition of pathways that regulate stress
responses in the endoplasmic reticulum [76,77].
Thus, HDACs are widely represented in the brain. Some of them are located in the nu-
clei of brain cells, some in the cytoplasm, and others in both the nucleus and the cytoplasm.
Their functions are different. The role of different HDAC isoforms in the survival and death
of brain cells after stroke is controversial. Some HDACs mediate survival processes, while
others are involved in neurotoxic reactions of cells after ischemic stroke. Some of them
can exhibit both neuroprotective and pathological properties depending on the type of
cell, their intracellular localization, and the nature of post-translational enzyme modifi-
cations. Expression of HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, Sirt1, and Sirt2 is
increased in the brain after ischemia. It is not known whether acetylation/deacetylation
of different HDACs occurs in brain cells and what their functional consequences are.
Further studies of changes in the dynamics and nature of HDAC interactions with each
other, with cytoplasmic proteins and with proteins of repressor complexes, are required.
Thus, there is a difference in the effects of HDAC inhibitors. They are effective in
the treatment of several types of cancer; promoting cancer cell apoptosis. On the other
hand, the neuroprotective effect of inhibitors is beyond doubt. To elucidate the reasons for
such differences, it is necessary to study the effect of reversible acetylation on the most
important transcription factors, the regulatory proteins involved in the survival or death of
nerve cells after ischemia.
7. Non-Histone Substrates of HAT and HDAC
Non-histone HAT/HDAC substrates include tumor suppressor proteins (e.g., p53,
RUNX3), signaling mediators (e.g., STAT3, β-catenin, SMAD7), steroid receptors (e.g., an-
drogens, estrogen, SHP), transcription factors, and coregulators (for example, c-Myc, HMG,
YY1, EKLF, E2F1, GATA factors, HIF-1α, MyoD, NF-κB, FoxB3), as well as structural (for
example, cell motility proteins), chaperone, and nuclear import proteins (e.g., α-tubulin,
importin-α, Ku70, HSP90) [3,4,78]. Acetylation of non-histone proteins can affect many
molecular functions of these proteins, such as mRNA splicing, mRNA transport and in-
tegrity, protein translation, protein activity, localization, stability and interactions [3,79,80],
and this list is updated every year. These proteins determine the growth, differentiation,
migration, and survival of cells, both in normal conditions and when damaged. Therefore,
acetylation-dependent signaling pathways are key determinants of homeostasis.
Proteomic studies of the expression of hundreds of proteins in the penumbra after
PTS indicate a consistent increase in the level of many signaling proteins that can initiate,
mediate, or regulate apoptosis, as well as a number of proteins with an antiapoptotic
effect [81,82]. The development of apoptosis was indicated by the increased expression of
proapoptotic proteins like p53, p38, p75, c-Myc, E2F1, JNK, AIF, Par4, DYRK1A, NMDAR2a,
GADD153, GAD65/67, Smac/DIABLO, caspases, and PSR, and a decrease in the level of
Hsp70. However, at the same time, the level of antiapoptotic proteins increased, including
receptors for growth factors EGFR and estrogens, protein kinases ERK 1 and 5, Akt,
phosphatase MKP-1, proteins p63, p21Waf-1, and MDM2. Many of these proteins are
acetylated and deacetylated.
The main proteins that play a central role in coordinating cell fate decisions are
considered in this review in more detail.
8. c-Myc
One of the main regulators of many target genes is the transcription factor c-Myc.
It activates (or sometimes suppresses) 10–15% of all genes involved in the regulation of en-
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ergy metabolism, protein synthesis, oncogenesis, the cell cycle, and apoptosis. It functions
at both the transcriptional and epigenetic level. It can potentiate apoptosis. c-Myc is an
oncogene in many human tumors [83]. c-Myc regulation can be involved in several signal-
ing pathways, such as JAK/STAT, Wnt/β-catenin, Notch, and the Ras/PI3K/AKT/GSK-3
signaling pathways, that increase c-Myc levels [84].
Its overexpression was also noted after transient global or focal cerebral ischemia in
rodents, where c-Myc promoted neuronal death [85]. An increase in the level of c-Myc was
observed in the penumbra on the first day after PTS [81].
The stability of c-Myc in different types of cancer cells is associated with its acety-
lation at lysine 323 by PCAF acetyltransferase (Figure 3) [86]. In lymphoma cells, SIRT1
interacted with the C-terminus of c-Myc and deacetylated it both in vitro and in vivo [87].
However, inhibitors of HDAC, but not sirtuins, increased the acetylation of c-Myc at lysine
323 and inhibited tumorigenesis [88], which promoted the association of c-Myc with Max, a
partner required for c-Myc activation. HDAC inhibitors downregulated c-Myc by blocking
GSK-3 phosphorylation and exhibited synergistic cytotoxic and c-Myc-suppressive effects
(Figure 4) [89]. HDAC3 also deacetylated c-Myc at lysine 323 in cholangiocarcinoma cells,
which protected the protein from ubiquitin-dependent proteolysis [90]. Thus, it can be as-
sumed that at least one of the HDACs in brain cells is c-Myc deacetylase. c-Myc stimulates
the expression of p53 and E2F1 [91].
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ylated by cyclic adenosine monophosphate response element-binding (CREB) protein (p300/CBP) 
and p300/CBP-associated factor (PCAF) acetyltransferases. Acetylation of p53 causes the activation 
of proapoptotic genes. Histone deacetylases HDAC1, HDAC2, HDAC3, HDAC8, and Sirtuin 1 
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sion of p53 and E2F1. E2F1 is acetylated by PCAF that increases protein specific binding to DNA. 
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resistance of different types of cells to damage. ERK1/2-extracellular signal-regulated kinases are 
acetylated by PCAF and deacetylated by HDAC6 which prevents cell apoptosis. Akt-protein kinase 
Bα is acetylated by p300 and PCAF. Akt is deacetylated by HDAC-3,-6,-8 and SIRT1. 
Figure 3. Proteins coordinating the cell fate decision under acetylation/deacetylation conditions.
The main proteins that play a central role in coordinating cell fate decisions are shown. p53 is
acetylated by cyclic adenosine monophosphate response element-binding (CREB) protein (p300/CBP)
and p300/CBP-associated factor (PCAF) acetyltransferases. Acetylation of p53 causes the activation of
proapoptotic genes. Histone deacetylases HDAC1, HDAC2, HDAC3, HDAC8, and Sirtuin 1 (SIRT1)
can deacetylate p53, which leads to a decrease in prot in ctivity and repression of transcription.
c-Myc is acetylated by PCAF. HDAC3 deacet lates c-Myc. c-Myc stimulates the expression of p53 and
E2F1. E2F1 is acetylated by PCAF that increases protein specific binding to DNA. E2F1 is deacetylated
by SIRT1 and HDAC1. Acetylation/deacetylation of E2F1 can contribute to the resistance of different
types of cells to damage. ERK1/2-extracellular signal-regulated kinases are acetylated by PCAF and
deacetylated by HDAC6 which prevents cell apoptosis. Akt-protein kinase Bα is acetylated by p300
and PCAF. Akt is deacetylated by HDAC-3,-6,-8 and SIRT1.
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Figure 4. Effect of acetylation/deacetylation on proteins involved in the regulation of apoptosis: c-Myc, p53, E2F1, ERK1/2
and Akt. Inhibitors (iHDAC), but not sirtuins, increase the acetylation of c-Myc at lysine 323 and inhibit tumorigenesis which
promotes the association of c-Myc with Max, a partner required for c-Myc activation. HDAC inhibitors downregulated
c-Myc by blocking GSK-3 phosphorylation. HDAC3 deacetylates c-Myc at lysine 323, protecting the protein from ubiquitin-
dependent pr teolysis. c-Myc stimulates the expression of p53 and E2F1. I hibition of the E2F1/p53 pathway prevents
neuronal apoptosis. E2F1 acetylated at three lysines (K117, 120, and 125) promotes DNA double- trand break repair.
The C-terminal lysines (K320, K373, K382) in p53 acetylatio increases p53 activity in response to DNA damage. Upon DNA
damage, the acetylation of p53 disrupts the interaction between Mdm2 and p53 and causes the activation of proapoptotic
genes. Sirtuin 1 (SIRT1) can reduce neuronal apoptosis and cerebral edema by deacetylating p53. The HDAC6 inhibition
reduces the amount of nuclear HDAC6 and therefore the interaction between HDAC6 and p53, which leads to an increase
in p53 acetylation. ERK1/2 acetylation at lysine 72 (K72) reduces the enzyme activity towards transcription factor ELK1, a
substrate of ERK1; ERK1/2 deacetylation by HDAC6 promotes ERK1 activation and prevents cell apoptosis. Protein kinase
Bα (Akt) is acetylated at lysines 163 and 377 (K163, K377). The inhibition of HDAC6 leads to a decrease in the ability of Akt
to bind PIP3. SIRT1 can also deacetylate and thus activate Akt a d the Akt/GSK3 signaling pathway. HDAC3 binds to Akt
and deacetylates it at lysine 20, promoting protein phosphorylation. Sirtuin1 (SIRT1) and Sirtuin2 (SIRT2) are involved in
the deacetylation of Akt at lysines 4 and 20, which leads to the activation of the enzyme.
9. E2F1
E2F1 transcription factor is one of the key players in determining the fate of the cell.
It controls the expression of various genes that regulate DNA synthesis and repair, the cell
cycle, and apoptosis [92,93]. E2F1 stimulates apoptosis when the cell cycle is disrupted or
suppressed, which is typical of neurons [94]. Its synthesis is controlled by the p38 MAP
kinase and the c-Myc transcription factor [95]. E2F1 induces the expression of various
proapoptotic proteins, such as caspases 3, 7, 8, and 9, Smac/DIABLO, Apaf-1, Bcl-2, p53,
and p73 [94,96]. Overexpression of E2F1, p53, c-Myc, p38, Smac/DIABLO, Bcl-x, caspases
3, 6, and 7 was observed in the penumbra on the first day after PTS [81]. This is consistent
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with data on the increased expression of E2F1 [97] and p53 [98] in the penumbra after
MCAO and in the axotomized spinal ganglia of rats [99]. Inhibition of the E2F1/p53
pathway prevents neuronal apoptosis [96].
iHDACs have been shown to affect E2F1 activity [100]. In cancer cells, in response to
genotoxic stress caused by doxorubicin, E2F1 is acetylated by PCAF at three lysines (K117,
120, and 125). This stabilizes the protein and increases its specific binding to DNA [101,102].
Acetylation of these lysines induces the accumulation of ubiquitinated but stable E2F1 [103].
Acetylation of E2F1 promotes the recruitment of chromatin-modifying enzymes and DNA
double-strand break repair factors [104].
HDAC1 acts as a deacetylase in different types of cancer cells [101,105,106]. In retinal
epithelial cells, E2F1 is deacetylated by Sirt1, which contributes to the resistance of cells
to oxidative stress caused by H2O2 [107]. Thus, acetylation/deacetylation of E2F1 can
contribute to the resistance of different types of cells to damage. However, in the literature
available to us, we failed to find information on the acetylation/deacetylation of E2F1 in
brain cells, either in normal conditions or in pathology.
10. p53
Protein p53 is the most studied non-histone HAT and HDAC substrate. p53 is a
known promoter of apoptosis. It controls the transcription of hundreds of genes involved
in the regulation of DNA repair, cell cycle arrest, metabolism, mRNA translation, apoptosis,
and autophagy [108]. The negative regulators of p53 are p21WAF-1, p67, and MDM2 [82].
The role of p53 acetylation/deacetylation in the regulation of gene expression and intracel-
lular signaling pathways is extremely important. p53 was the first non-histone protein to
be discovered with activity that was dependent on acetylation. In different types of cancer
cells, the C-terminal lysines in p53 are acetylated by p300/CBP (lysines 373 and K382) and
PCAF (lysine 320) both in vitro and in vivo [109]. Acetylation of p53 significantly enhances
its activity in response to DNA damage. In normal cells, unacetylated p53 can activate
genes that are involved in its downregulation, for example, Mdm2. Upon DNA damage,
the acetylation of p53 disrupts the interaction between Mdm2 and p53 and recruits HAT to
the promoters of genes involved in DNA repair and cell cycle control. Acetylation of p53
causes the activation of proapoptotic genes.
In different types of oncotransformed cells, it has been shown that HDAC1, HDAC2,
HDAC3, HDAC6, HDAC8, and SIRT1 can deacetylate p53, which leads to a decrease in
protein activity and the repression of transcription [110–112]. In colorectal cancer cells,
HDAC6 deacetylates p53 at lysines 381/382. The C-terminal lysine residues within p53 also
deacetylate HDAC1, HDAC2, and SIRT1. Romidepsin, a specific inhibitor of HDAC1/2,
enhances p53 acetylation at lysines 320/372, but not lysines 381/382. SIRT1 preferentially
deacetylates p53 at lysine 382 [113]. A decrease in the level of acetylated p53 in patients
with colorectal cancer is associated with an increase in HDAC6 expression. The HDAC6
inhibitor A452 reduces the amount of nuclear HDAC6 and therefore the interaction between
HDAC6 and p53, which leads to an increase in p53 acetylation at lysines 381/382.
Sumoylation of HDAC2 at lysine 462 in colorectal carcinoma cells allows HDAC2
to bind to p53. Deacetylation of p53 at lysine 320 by sumoylated HDAC2 blocks p53-
dependent expression of genes for cell cycle control and apoptosis, reducing apoptosis
caused by DNA damage [114]. Genotoxic stress induces desumoylation of HDAC2, which
activates p53 and stimulates apoptosis. In lymphoma cells, p53 interacts with HDAC1,
HDAC3, and HDAC8 and becomes deacetylated, which reduces their apoptosis [110,115].
Autophagic feedback-mediated degradation of one of the catalytic subunits of the IκB
kinase requires p300/CBP-dependent acetylation of p53 during arsenite-induced proapop-
totic responses in human hepatoma cells [55].
In a rat model of hemorrhagic stroke, it was shown that SIRT1 can reduce neuronal
apoptosis and cerebral edema by deacetylating p53 [116]. Thus, acetylation/deacetylation
regulates p53 activity by altering the expression of target genes. Moreover, in different
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types of cells, different isoforms of HAT and HDAC are involved in protein acetyla-
tion/deacetylation.
11. ERK1/2
It is known that some of the non-histone substrates of HDAC6 are the protein kinases
ERK1 and ERK2, which provide the resistance of nervous tissue to ischemic damage [82].
ERK1 can phosphorylate HDAC6, thereby increasing HDAC6-mediated tubulin deacety-
lation. In turn, ERK1/2 are acetylated by PCAF at lysine 72, which reduces the enzyme
activity towards the transcription factor ELK1. This is a well-known substrate of ERK1,
and is deacetylated by HDAC6, which promotes ERK1 activation and prevents cancer cell
apoptosis [117]. It has been shown that an inhibition of HDAC1 and HDAC6 downregu-
lated the expression of phospho-ERK1 in human head and neck squamous cell carcinoma
cells [118].
12. Akt
Another non-histone substrate of HDAC6 with antiapoptotic activity is protein kinase
Bα (Akt). In response to brain ischemia, an increase in Akt expression is observed in
penumbral cells [81,119,120]. In human neuronal progenitor cells, Akt is acetylated at
lysines 163 and 377 in the kinase domain of the enzyme [121]. The inhibition of HDAC6
can lead to a decrease in the ability of Akt to bind PIP3, which is located in the plasma
membrane. This is accompanied by a decrease in the ability of Akt to phosphorylate
downstream targets, even when the protein is phosphorylated at serine 473, which usually
enhances the catalytic activity of the enzyme [122]. It has been shown that HDAC inhibition
by sodium butyrate did not influence the expression of Akt and phospho-Akt in the brain
after hypoxic-ischemic brain injury in rats [123].
SIRT1 can also deacetylate and thus activate Akt and the Akt/GSK3 signaling pathway,
which promotes axon growth and formation in embryonic hippocampal neurons [124].
In myocardial cells, Sirt1 and Sirt2 are involved in the deacetylation of Akt at lysines 14
and 20, which leads to the activation of the enzyme [125].
In cancer cells, Akt is acetylated by histone acetyltransferases p300 and PCAF at
lysines 14 and 20 [126]. HDAC3 binds to Akt and deacetylates it at lysine 20, promot-
ing protein phosphorylation. Exposure to chemotherapy drugs enhances the interaction
between HDAC3 and Akt, which leads to a decrease in Akt acetylation, an increase in
its phosphorylation, and a decrease in the sensitivity of leukemic cells to apoptosis [127].
In contrast, HDAC3 inhibitors increase the sensitivity of cancer cells to apoptosis after
chemotherapy caused by chemotoxicity. HDAC8 is also able to interact with Akt, reducing
its acetylation at lysine 426 in breast cancer cells [128].
Cancer studies indicate that the acetylation of anti- and proapoptotic proteins promote
apoptosis, and their deacetylation promotes survival and proliferation. Therefore, HDAC
inhibitors have therapeutic potential in cancer treatment [129].
13. Conclusions and Outlook
The transcription factors and signaling proteins that play an important role in brain
cell responses to ischemia undergo acetylation/deacetylation. In different cell types, the
acetylation/deacetylation of different regions of non-histone proteins containing lysines
occurs and HAT/HDAC activity depends on the acetylation site. Moreover, the activity of
the HDACs themselves can be regulated by their acetylation/deacetylation. Depending
on the acetylation site localization in structural and functional regions of the protein,
reversible acetylation can change the activity of the protein, the substrate binding, the
intracellular localization, etc.; therefore, the cell response to ischemia depends on the site
of the acetylation.
The vast majority of data on non-histone protein acetylation/deacetylation have been
obtained in cancer cells. Data on the effects of stroke on non-histone protein acetyla-
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tion/deacetylation in brain cells are extremely limited and practically absent. This is an
area for further research.
The search for HAT and HDAC isoforms that are capable of acetylating/deacetylating
the signaling proteins and transcription factors that regulate apoptosis and other essential
functions of brain cells after stroke will contribute to the development of effective neuro-
protective therapies based on selective iHDACs. It will also contribute to the search for
new substrates and tissue-specific HDAC and HAT inhibitors or activators for treating the
consequences of stroke at different periods of the disease.
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